All-In Podcast
Industry veterans, degenerate gamblers & besties Chamath Palihapitiya, Jason Calacanis, David Sacks & David Friedberg cover all things economic, tech, political, social & poker.
Dave Ricks, CEO of Eli Lilly | The All-In Interview
David Friedberg engages in a conversation with Eli Lilly CEO Dave Ricks, exploring the global obesity epidemic and the discovery of GLP-1s. They discuss the effects of GLP-1s on various human functions and delve into the commercial aspects of drug discovery, including pricing strategies. The episode addresses criticism and research surrounding GLP-1 dependency, as well as the company's stock performance and political pressures tied to successful drugs. Dave Ricks shares insights on Eli Lilly's diverse drug portfolio beyond GLP-1s and the scientific advancements that excite him. The episode concludes with a discussion on scaling and influencing culture in a company with over a century of history.
Key Points
- Eli Lilly's GLP-1 drug market is projected to grow significantly, with potential applications extending beyond diabetes and obesity to other chronic health conditions.
- Eli Lilly is heavily investing in research and development, including innovative approaches like gene therapy and siRNA, to expand their portfolio and address a wide range of diseases.
- The company is focused on maintaining a strong organizational culture and operational speed while navigating the complexities of healthcare policy and societal expectations regarding drug pricing and accessibility.
Chapters
| 0:00 | |
| 2:06 | |
| 13:07 | |
| 20:38 | |
| 27:09 | |
| 33:11 | |
| 40:04 | |
| 47:19 | |
| 56:09 |
Transcript
Loading transcript...
- / -